• Powered by Crown Equity Holdings Inc.
      • crown-logo

        Crown Equity Holdings Inc. is publicly traded with the symbol CRWE. The Company primarily provides and offers advertising, branding, marketing solutions and services to boost customer awareness, as well as merchant visibility as a worldwide online multi-media publisher. For list of services offered click here

Post on CRWE World Login
logo Fairfield, UNITED STATES
header-img
  • Home
  • News
  • World
      • World News
      • Español
  • Politics
      • U.S. Legislators
      • Political News
  • Sports
  • Business
      • Markets
      • Hottest Stocks Today
      • CRWEWorld Stocks
      • Blockchain
      • Regulatory
      • Accounting
      • Fundraising Campaigns
      • IPOs
      • Money
      • Career
  • Tech
      • Tech
      • Science
  • Living
      • Arts & Entertainment
      • Family
      • Food
      • Pets
      • Seniors
      • Fashion/Fitness
      • Home & Garden
  • Health
      • Health
      • Pharma & Biotech
  • Opinion
      • Finance
      • Law
      • Healthcare
      • Cannabidiol (CBD)
      • Fashion
      • Podcasts
      • Tech
      • Music
  • Travel
  • Local
      • News
      • Trending Now
      • Real Estate
      • Coupons & Deals
      • Business Directory
  • Jobs
  • More
      • Business 2 Business
      • Press Releases
      • Press Releases Pricing
      • News from GlobeNewswire
      • News from PR Newswire
      • News from Business Wire
      • News from Accesswire
      • Video Channels
      • Beauty
      • Business
      • Comedy
      • Entertainment
      • Fashion
      • Featured
      • Health
      • Instructional
      • News
      • Politics
      • Sports
      • Technology
      • Entertainment
      • Horoscope
      • Sudoku
      • Crossword
      • Games
      • Chat
      • Affiliate | How It Works
      • Join CRWE WORLD Affiliate Program
      • CRWE WORLD Advertising Services Rate
      • Crown Equity Holdings' Overview
      • CRWEWorld Real-Time Global Visitors
      • Content Delivery Solution
        • Contact Us
  • More

Change City


-- OR --
load
load
/assets/img/hottest3.png
/assets/img/hottest2.png

/assets/img/reef2.png
/assets/img/red-line.jpg
/assets/img/reef.png
  • Home
  • Articles
  • News Provided by PR Newswire
21ьз╕ Cweather-icon
/assets/img/hottest3.png
/assets/img/hottest2.png

/assets/img/reef2.png
/assets/img/red-line.jpg
/assets/img/reef.png

ProMIS Neurosciences Unique Discovery Platform Generates Potential New Antibody Therapeutics for Neurodegenerative Diseases

News Provided by PR Newswire2018-06-26
74 Views

ProMIS Neurosciences Unique Discovery Platform Generates Potential New Antibody Therapeutics for Neurodegenerative Diseases

 
[26-June-2018]
 

Antibody Candidates Targeting Toxic Oligomers Implicated in Parkinson's Disease and Amyotrophic Lateral Sclerosis (ALS) Advance to the Final Stage of ProMIS Discovery Platform

TSX:PMN; OTCQB: ARFXF

TORONTO and CAMBRIDGE, MA, June 26, 2018 /PRNewswire/ - ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of treatments for neurodegenerative diseases, announced today that numerous antibodies against two new targets in neurodegenerative diseases have entered the final stage of discovery. These antibody candidates target the aggregated, toxic oligomers of alpha-synuclein, implicated in the development of Parkinson's disease (PD), as well as TDP43 (TAR DNA binding protein), implicated in the development of ALS.

ProMIS Neurosciences Inc. (CNW Group/ProMIS Neurosciences Inc.) (CNW Group/ProMIS Neurosciences Inc.) (CNW Group/ProMIS Neurosciences Inc.)

"ProMIS' proprietary discovery platform consists of two stages" according to Dr. Neil Cashman, ProMIS Chief Scientific Officer. "The first stage involves predicting novel epitope targets and using these to generate large numbers of candidate antibodies. The second stage is to validate selectivity, functional activity, and select the best leads. We are very pleased with our progress so far in identifying epitopes displayed by the two additional toxic oligomers that are the root cause of these devastating diseases and are moving into the validation and selection phase with these targets." 

Hundreds of monoclonal antibodies have been generated against these predicted disease-specific epitopes and ProMIS has now begun the validation and prioritization process to select therapeutic candidates displaying an ideal, highly selective product profile against these targets.

"The outstanding efficiency of our unique discovery platform is exemplified by the success of our lead Alzheimer's disease program which led to the rapid identification and validation of PMN310, our therapeutic antibody candidate that is selective for toxic oligomers of amyloid beta, a root cause of AD," said Johanne Kaplan, ProMIS Chief Development Officer. "We are applying a similar, rigorous evaluation process to the numerous antibody candidates against toxic oligomers of alpha-synuclein and TDP43 and anticipate generating the scientific data required to select the best lead(s) over the coming months."

"This progress exemplifies the power of our unique discovery platform and will help us carry out the corporate strategy we have articulated," said Gene Williams, ProMIS Executive Chairman. "We are actively pursuing discussions with large pharma regarding partnering of these two new toxic oligomer programs."

Native TDP43 is normally found in the nucleus of all cells, including nerve cells. In ALS, misfolded, TDP43 aggregates (oligomers) mislocalize to the cytoplasm of the neuron where their presence correlates with cell death. These toxic forms of TDP43 can also propagate from nerve cell to nerve cell in prion-like fashion.

Parkinson's disease is a progressive neurodegenerative disorder characterized by loss of dopaminergic neurons located in the midbrain and the presence of neuronal inclusions (Lewy bodies/Lewy neurites) consisting mainly of aggregates of alpha-synuclein. Recent evidence suggests that alpha-synuclein toxicity resides primarily with the oligomeric form and not monomers or insoluble fibrils. Aggregated, toxic alpha-synuclein can also propagate in a prion-like manner.

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a development stage biotechnology company focused on discovering and developing precision medicine therapeutics to treat neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). The Company's proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics for AD, ALS and PD.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN.TO, and on the OTCQB Venture Market under the symbol ARFXF.

For further information please consult the Company's website at:  www.promisneurosciences.com

Follow us on Twitter

Like us on LinkedIn

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.  This news release contains certain "forward-looking statements" within the meaning of Canadian securities legislation. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words "expects", "plans", "anticipates",  believes", "intends", "estimates", "projects", "aims", "potential", "goal", "objective", "prospective", and similar expressions, or that events or conditions "will", "would", "may", "can", "could" or "should" occur. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except as required by the securities disclosure laws and regulations applicable to the Company, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors, should change.

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/promis-neurosciences-unique-discovery-platform-generates-potential-new-antibody-therapeutics-for-neurodegenerative-diseases-300671620.html

SOURCE ProMIS Neurosciences Inc.


Company Codes: OTC-QB:ARFXF, Toronto:PMN


© 2018 PR Newswire. All Rights Reserved.

#content-news .main-news{color:#737373;font-size:14px;line-height:inherit;text-align:inherit}

The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.


Berkshire Hathaway Inc. (NYSE: BRK.A) (NYSE: BRK.B) Reports Fourth Quarter and Full Year 2020



/assets/img/cw-stocks.png

/assets/img/wysh-jewels.png

/assets/img/hjli.png

/assets/img/Mars-Parachute-2.png

/assets/img/crweworld-podcast.jpg
Sponsored
Also read
BrainChip’s Success in 2020 Advances Fields of On-Chip Learning and Ultra-Low Power Edge AI
USD Partners LP Announces Fourth Quarter and Full Year 2020 Results
CorEnergy Announces 2020 Results and Affirms Outlook
GigCapital2 Announces Postponement of Special Meeting of Stockholders
CompuCom Issues Statement Regarding Malware Incident
Entravision Communications Corporation Announces Quarterly Cash Dividend
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AgEagle Aerial Systems, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – UAVS
Hess Announces Regular Quarterly Dividend On Common Stock


Post on CRWE WorldSign Up for Free E-mail Updates
  • Real Estate Eagle Firm, Real Estate
  • Hancock Jaffe Laboratories, Nasdaq:HJLI, HJLI
Signup for free email updates
/assets/img/wall-street-rect2.png
/assets/img/wall-street-sq.png



Join with us
Live Traffic Feed
About CrweWorld
  • About Us
  • Privacy Policy
  • Terms & Conditions
  • Finance Disclaimer
  • Jobs
Subscribe for newsletter
3+2
Contact Info
  • contact@crweworld.com

  • P: (702) 683-8946

  • P: (702) 810-0178

  • 11226 Pentland Downs St, Las Vegas, NV 89141

Tweets by CrweWorld
Tweets by @CrweWorld
  • © 2021 crweworld.com
ad1

/assets/images/ad/crwe_tech.jpg

Your Technology Source, Your Technology Team

Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more

Contact Us: contact@crwetech.com

www.CRWETech.com

ad2

/assets/images/ad/content-delivery-solution.jpg

 

Our content delivery solution through CRWE WORLD, CRWE Press Release and CRWE Tube gives corporations and businesses a vehicle to expand their exposure

CLICK HERE FOR MORE INFORMATION

ad3

/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

/assets/images/ad/crwetube.png

Share your videos. Upload your videos for free on CRWETube

www.CRWETube.com

ad5

/assets/images/ad/ad4.png

 

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

Advertisements

/assets/images/ad/crwe_tech.jpg

Your Technology Source, Your Technology Team

Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more

Contact Us: contact@crwetech.com

www.CRWETech.com

/assets/images/ad/content-delivery-solution.jpg

 

Our content delivery solution through CRWE WORLD, CRWE Press Release and CRWE Tube gives corporations and businesses a vehicle to expand their exposure

CLICK HERE FOR MORE INFORMATION

/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

/assets/images/ad/crwetube.png

Share your videos. Upload your videos for free on CRWETube

www.CRWETube.com

/assets/images/ad/ad4.png

 

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

CRWE WORLD Advertising Services RateJoin CRWE WORLD Affiliate Program